Immunoconjugates for treating diseases associated with neovascularization suchas cancer, rheumatoid arthritis, the exudative form of macular degeneration,and atherosclerosis are described. The immunoconjugates typically consist ofthe Fc region of a human IgG1 immunoglobulin including the hinge, or othereffector domain or domains that can elicit, when administered to a patient, acytolytic immune response or cytotoxic effect against a targeted cell. Theeffector domain is conjugated to a targeting domain which comprises a factorVII mutant that binds with high affinity and specificity to tissue factor butdoes not initiate blood clotting such as factor VII having a substitution ofalanine for lysine-341 or of alanine for serine-344.
